Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seasoned electrophysiology commercial leader joins the Company to expand operating capabilities Seasoned electrophysiology commercial leader joins the Company to expand operating capabilities

BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

BioSig Technologies Inc, the medtech group, has announced another boost for its heart monitoring technology, revealing that the US Patent Office had awarded patent claims for its PURE EP noise-filtering technology. The patent application was filed on November 6 last year and describes and claims computer-implemented methods for filtering noise from an input signal.

BioSig Technologies receives boost for its PURE EP technology with award of patent claims

Westport, CT, Jan. 26, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the US Patent Office had allowed a utility patent covering its PURE EP™ noise-filtering technology. The recently allowed patent application number 17/091,357 entitled “Universal Notch Filter " was filed on November 6, 2020. The patent describes and claims computer-implemented methods for filtering noise from an input signal.

BioSig Awarded US Patent Claims for its PURE EP™ Noise-Filtering Technology

PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health

BioSig to Present at the 27th Annual International AF Symposium

BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System. BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System.

BioSig to Present at the 24th Annual Virtual Needham Growth Conference

Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites.  What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.

BioSig Technologies looking to unlock the future of bioelectronic medicine

BioSig Technologies Inc has announced the appointment of Access Strategy Partners, Inc (ASPI) to advise the company on the next phase of its commercial roll-out. BioSig said the healthcare management firm is expected to enhance the company's market access strategy as BioSig expands the installation base of its signal processing technology for arrhythmia care.

BioSig Technologies selects Access Strategy Partners to accelerate commercial sales

Leading healthcare management firm to enhance the Company's market access strategy as it expands the installation base of its signal processing technology for arrhythmia care Leading healthcare management firm to enhance the Company's market access strategy as it expands the installation base of its signal processing technology for arrhythmia care

BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales

BioSig Technologies Inc said that it is installing a PURE EP System for an evaluation at the Hospital Corporation of America (HCA) Healthcare-operated Westside Regional Medical Center in Plantation, Florida. Westside Regional Medical Center is an award-winning, 250-bed hospital recognized for providing a wide array of services to the residents of Broward County, South Florida, and visitors from around the world.

BioSig Technologies expands its clinical footprint in Florida, installs PURE EP System in HCA Healthcare-operated hospital

The Company's signal processing technology for arrhythmia care is being installed in a leading HCA Healthcare-operated facility in Southeast Florida The Company's signal processing technology for arrhythmia care is being installed in a leading HCA Healthcare-operated facility in Southeast Florida

BioSig Expands Its Clinical Footprint In Florida

Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET.

BioSig to Host Conference Call on December 21, 2021

Westport, CT, Dec. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc., would be presenting at the Benzinga All Access event on Tuesday, December 14, 2021, at 9:40 am EST.

BioSig to Participate in the Benzinga All Access Event on December 14, 2021

BioSig Technologies Inc has announced that Gray Fleming will be joining the company as its chief commercial officer. The Westport, Connecticut-based company said that Fleming will bring over 20 years of experience in the healthcare industry.

BioSig Technologies appoints Gray Fleming as chief commercial officer

Seasoned electrophysiology sales executive joins the Company to expand the commercial footprint of its signal processing technology for arrhythmia care Seasoned electrophysiology sales executive joins the Company to expand the commercial footprint of its signal processing technology for arrhythmia care

BioSig Technologies, Inc. Appoints Gray Fleming as Chief Commercial Officer

Westport, CT, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in The Benchmark Company 10th Annual Discovery One on One Investor Conference (Virtual) on Thursday, December 2, 2021.

BioSig to Participate in the The Benchmark Company 10th Annual Discovery Conference

BioSig Technologies Inc said it has entered into a feasibility study with Haifa, Israel-based Technion Research & Development Foundation Ltd. The Westport, Connecticut-based company said that the feasibility program will be led by Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at Technion.

BioSig Technologies initiates Artificial Intelligence Development Program with Israel-based Technion

Company partners with the leading academic institution on research and development of AI-driven methods for atrial fibrillation procedures Company partners with the leading academic institution on research and development of AI-driven methods for atrial fibrillation procedures

BioSig Initiates Artificial Intelligence Development Program with Technion – Israel Institute of Technology

Discussion led by three industry experts scheduled for November 18, 2021 at 8pm ET Discussion led by three industry experts scheduled for November 18, 2021 at 8pm ET

BioSig to Host Live Roundtable Webinar to Discuss Clinical Data Delivered With Its Signal Processing Technology For Arrhythmia Care

BioSig Technologies Inc announced that it is installing the company's seventeenth PURE EP system —  a computerized system measuring and calculating electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures — for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, Texas. Opened in 2019, Medical City Heart Hospital — a cardiovascular department of Medical City Dallas Hospital — provides the most comprehensive heart and vascular treatment in the Southwest.

BioSig Technologies adds to its growing clinical footprint in Texas

The Company's signal processing technology for arrhythmia care is being installed in a highly ranked hospital in Dallas The Company's signal processing technology for arrhythmia care is being installed in a highly ranked hospital in Dallas

BioSig Adds To Its Clinical Footprint In Texas

BioSig Technologies Inc has said it is installing its PURE EP system for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. The company noted that BIDMC is a world-class teaching hospital of Harvard Medical School, with more than 4,000 physicians and 35,000 employees.

BioSig Technologies installs its PURE EP system at renowned Boston medical center

Latest installation follows a steady rise in patient cases conducted with the PURE EP™ System Latest installation follows a steady rise in patient cases conducted with the PURE EP™ System

BioSig Installs its Signal Processing Technology for Arrhythmia Care at a Leading Hospital in Boston

BioSig Technologies Inc said it is installing its PURE EP system for an evaluation at the Methodist Hospital in San Antonio, Texas, one of the largest hospitals in the US in terms based on the number of available beds. The company noted it now has 15 installed centers following the 90-day evaluation agreement with Methodist Hospital.

BioSig Technologies expands its PURE EP installation base in Texas

Signs a new installation agreement with high-volume center in San Antonio Signs a new installation agreement with high-volume center in San Antonio

BioSig Expands its Installation Base in Texas

BioSig Technologies Inc said that its PURE EP System has exceeded its procedural target of 1,500 patient cases in 2021. As of October 21, 2021, the PURE EP System had been used in over 1,560 patient cases by 71 physicians, up from 1,000 cases in June 2021, when the procedural guidance was raised amid increased technology usage in elective procedures.

News for Biosig Technologies Inc Stock (BSGM)